Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants

Clinical Chemistry

Volumn 56, Issue 2, 2010, Pages 281-290

  Lopez, Mary F ^a   Rezai, Taha ^a   Sarracino, David A ^a   Prakash, Amol ^a   Krastins, Bryan ^a   Athanas, Michael ^b   Singh, Ravinder J ^c   Barnidge, David R ^c   Oran, Paul ^d   Borges, Chad ^d   Nelson, Randall W ^d,e  

^a Thermo Fisher Scientific   (United States)

^b VAST Scientific   (United States)

^c Mayo Clinic   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

^e Intrinsic Bioprobes   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE;

AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY FAILURE; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

AGED; AMINO ACID SEQUENCE; AREA UNDER CURVE; FEMALE; HUMANS; IMMUNOASSAY; KIDNEY FAILURE, CHRONIC; LIMIT OF DETECTION; MALE; MOLECULAR SEQUENCE DATA; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 75749115605     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.137323     Document Type: Article

References (30)

1. Aloia JF, Feuerman M, Yeh JK. Reference range for serum parathyroid hormone. Endocr Pract 2006;12:137-44.
2. Soldin SJ, Brugnara C, Gunter KC, Hicks JM. Pediatric reference ranges. 2nd ed. Washington (DC): AACC Press; 1997. p 119.
3. Fraser WD. Hyperparathyroidism. Lancet 2009; 374:145-58.
4. Brown RC, Aston JP, St John A, Woodhead JS. Comparison of poly- and monoclonal antibodies as labels in a two-site immunochemiluminometric assay for intact parathyroid hormone. J Immunol Meth 1988;109:139-44.
5. Endres DB, Villanueva R, Sharp CF Jr, Singer FR. Immunochemiluminometric and immunoradiometric determinations of intact and total immunoreactive parathyrin: performance in the differential diagnosis of hypercalcemia and hypoparathyroidism. Clin Chem 1991;37:162-8.
6. Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987;33:1364-7.
7. Boudou P, Ibrahim F, Cormier C, Chabas A, Sarfati E, Souberbielle JC. Third- or secondgeneration parathyroid hormone assays: a remaining debate in the diagnosis of primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90:6370-2.
8. Gao P, D'Amour P. Evolution of the parathyroid hormone (PTH) assay: importance of circulating PTH immunoheterogeneity and of its regulation. Clin Lab 2005;51:21-9.
9. Borges CR, Rehder DS, Jarvis JW, Schaab MR, Oran PE, Nelson RW. Full-length characterization of proteins in human populations. Clin Chem 2010;56:202-11.
10. Langub MC, Monier-Faugere MC, Wang G, Williams JP, Koszewski NJ, Malluche HH. Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology 2003;144:1135-8.
11. D'Amour P. Circulating PTH molecular forms: what we know and what we don't. Kidney Int Suppl 2006;S29-33.
12. John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Juppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999;84:4287-90.
13. Salusky IB, Goodman WG. Adynamic renal osteodystrophy: is there a problem? J Am Soc Nephrol 2001;12:1978-85.
14. Winer KK, Yanovski JA, Cutler GB Jr. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA 1996;276:631-6.
15. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
16. Miller PD, Bilezikian JP, Deal C, Harris ST, Ci RP. Clinical use of teriparatide in the real world: initial insights. Endocr Pract 2004;10:139-48.
17. Nelson RW, Krone JR, Bieber AL, Williams P. Mass spectrometric immunoassay. Anal Chem 1995;67:1153-8.
18. Kiernan UA, Nedelkov D, Tubbs KA, Niederkofler EE, Nelson RW. Selected expression profiling of full-length proteins and their variants in human plasma. Clin Proteomics J 2004;1:7-16.
19. Kiernan UA, Tubbs KA, Nedelkov D, Niederkofler EE, Nelson RW. Detection of novel truncated forms of human serum amyloid A protein in human plasma. FEBS Lett 2003;537:166-70.
20. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW. Investigating diversity in human plasma proteins. Proc Natl Acad Sci U S A 2005; 102:10852-7.
21. Nedelkov D, Phillips DA, Tubbs KA, Nelson RW. Investigation of human protein variants and their frequency in the general population. Mol Cell Proteomics 2007;6:1183-7.
22. Niederkofler EE, Kiernan UA, O'Rear J, Menon S, Saghir S, Protter AA, et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail 2008;1:258-64.
23. Zhang CX, Weber BV, Thammavong J, Grover TA, Wells DS. Identification of carboxyl-terminal peptide fragments of parathyroid hormone in human plasma at low-picomolar levels by mass spectrometry. Anal Chem 2006;78:1636-43.
24. Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson TW. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J Proteome Res 2004;3:235-44.
25. Berna M, Schmalz C, Duffin K, Mitchell P, Chambers M, Ackermann B. Online immunoaffinity liquid chromatography/tandem mass spectrometry determination of a type II collagen peptide biomarker in rat urine: Investigation of the impact of collision-induced dissociation fluctuation on peptide quantitation. Anal Biochem 2006;356:235-43.
26. Oe T, Ackermann BL, Inoue K, Berna MJ, Garner CO, Gelfanova V, et al. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 2006;20:3723-35.
27. Ackermann BL, Berna MJ. Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers. Expert Rev Proteomics 2007;4:175-86.
28. Berna M, Ackermann B. Increased throughput for low-abundance protein biomarker verification by liquid chromatography/tandem mass spectrometry. Anal Chem 2009;81:3950-6.
29. Nelson RW. The use of bioreactive probes in protein characterization. Mass Spectrometry Rev 1997;16:353-76.
30. Lopez MF, Kuppusamy R, Sarracino DA, Prakash A, Athanas M, Krastins B, et al. Discovery and targeted SRM assay development of firsttrimester peptide biomarker candidates for trisomy 21 in maternal blood. Mol Cell Proteomics. Forthcoming 2010.